We are a developmental stage biopharmaceutical and cryptocurrency company. Our therapeutics focus is on developing novel therapeutics that address underserved conditions including PTSD, stress-induced anxiety disorders, fibromyalgia, and central nervous system (CNS) diseases.
Status note Lead product candidate. Pre-IND briefing package and meeting request submitted Jun 4, 2024; pre-IND meeting with FDA held Sep 2024 to align on the 505(b)(2) regulatory pathway. Studies required to support an IND submission completed; advancing toward human clinical trials.
SPU-16
Stage not disclosed · TerminatedModality: central nervous system-homing peptides
Partnerships University of Maryland, Baltimore: Master License Agreement (Feb 12, 2021) terminated Jul 8, 2025; subsequent exclusive option to negotiate a new commercial license expired unexercised on Mar 31, 2026
Indications
Multiple sclerosis(Stage not disclosed)
Other neuroinflammatory pathology(Stage not disclosed)
Status note UMB license terminated Jul 8, 2025 and the option to negotiate a new license expired unexercised Mar 31, 2026; Silo no longer holds rights to this asset.
SP-26
Stage not disclosed · Active
Indications
Chronic pain, including fibromyalgia(Stage not disclosed)
Status note Provisional patent application filed Mar 2023; intended for development under the FDA 505(b)(2) regulatory pathway for repurposed drugs.
Per-asset detail extracted from the 10-Q filed 2026-08-13. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
No lead program on file for this company.
No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.
Specialist fund holders
Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.
None of the tracked specialist funds reported a position in the latest 13F snapshot.
Latest news
Loading headlines…
Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.
Get the weekly biotech catalyst rundown. Cash runways, financings, and trial readouts for all 721 stocks.